Early Postoperative Minimal Residual Disease Detection with MAESTRO Is Associated with Recurrence and Worse Survival in Patients with Head and Neck Cancer.

doi:10.1158/1078-0432.CCR-25-0307

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Early Postoperative Minimal Residual Disease Detection with MAESTRO Is Associated with Recurrence and Worse Survival in Patients with Head and Neck Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Aug 2025

Sim Edward S, Rhoades Justin, Xiong Kan, Walsh Laurel, Crnjac Andjela, Blewett Timothy, Al-Inaya Yana, Mendel Julia, Ruiz-Torres Daniel A, Efthymiou Vasileios, Lumaj Gjystina, Benjamin William J, Makrigiorgos G Mike, Tabrizi Shervin, Adalsteinsson Viktor A, Faden Daniel L

Abstract excerpt

PURPOSE: Although ctDNA is a promising biomarker for minimal residual disease (MRD) detection in head and neck squamous cell carcinoma (HNSCC), more sensitive assays are needed for accurate MRD detection at clinically relevant time points. Ultrasensitive MRD detection early after surgery could guide adjuvant therapy decisions, but early ctDNA dynamics are poorly understood. EXPERIMENTAL DESIGN: We applied minor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Head and Neck Neoplasms

Share to Neoplasm Recurrence, Local

Share to Neoplasm, Residual

Share to Postoperative Period

Share to Squamous Cell Carcinoma of Head and Neck

Share to Whole Genome Sequencing

Source

Open in PubMed Open full text

Identifiers

PMID: 40392096
DOI: 10.1158/1078-0432.CCR-25-0307
PMCID: PMC12353190

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early Postoperative Minimal Residual Disease Detection with MAESTRO Is Associated with Recurrence and Worse Survival in Patients with Head and Neck Cancer.PMID 40392096Read ↗

Immediate postoperative minimal residual disease detection with MAESTRO predicts recurrence and survival in head and neck cancer patients treated with surgerySemantic proximity Read ↗

Postoperative Lymph is a Proximal Source of ctDNA for Detection of Recurrence in HPV-independent Head and Neck CancerSemantic proximity Read ↗

Tumour informed workflow to use ctDNA as a biomarker for risk of recurrence in head and neck cancer patients post-treatmentSemantic proximity Read ↗

Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA.Semantic proximity Read ↗

Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.Semantic proximity Read ↗

Personalized circulating tumor DNA dynamics predict survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancerSemantic proximity Read ↗

Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).Semantic proximity Read ↗

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerSemantic proximity Read ↗

MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies.Semantic proximity Read ↗

Molecular Residual Disease in Non‐Small Cell Lung Cancer: Technology or Patient Outcomes?Semantic proximity Read ↗

Detection of residual disease after neoadjuvant therapy in breast cancer using personalized circulating tumor DNA analysisSemantic proximity Read ↗

Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.